CSL’s Limited
(ASX:CSL) first half net profit has shot up 19 per cent to $US1.2 billion, despite an unfavourable foreign exchange impact.
The blood products and vaccine supplier is tipping profit growth of 10 per cent for the current year in the face of economic headwinds weighing on trading condition.
On a constant currency basis, net profit grew 21 per cent, slightly ahead of the company's guidance of 20 per cent.
Revenue rose to $US5.1 billion, from $US4.8 billion in the prior year.
Chief executive officer Paul Perreault said trading conditions would be tempered by economic headwinds and says earnings per share growth will eclipse expected profit growth.
CSL will pay an unfranked final dividend of 52 US cents, pushing the total dividend to $US1.02, an 18 per cent lift on the previous year.
